Literature DB >> 12121958

Induction of apoptosis by a nonnucleoside human immunodeficiency virus type 1 reverse transcriptase inhibitor.

A A Pilon1, J J Lum, J Sanchez-Dardon, B N Phenix, R Douglas, A D Badley.   

Abstract

Inhibition of human immunodeficiency virus type 1 reverse transcriptase (RT) by both nucleoside and nonnucleoside RT inhibitors profoundly inhibits virus replication. Nucleoside RT inhibitors are known to be toxic, but there is little information regarding the toxicities of nonnucleoside RT inhibitors (NNRTI). We demonstrate that efavirenz (an NNRTI) induces caspase- and mitochondrion-dependent apoptosis of Jurkat T cells and human peripheral blood mononuclear cells. The clinical relevance of these observations is not yet clear.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12121958      PMCID: PMC127389          DOI: 10.1128/AAC.46.8.2687-2691.2002

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  21 in total

1.  Apoptosis. Mitochondria--the death signal integrators.

Authors:  C Brenner; G Kroemer
Journal:  Science       Date:  2000-08-18       Impact factor: 47.728

2.  Risks and benefits of replacing protease inhibitors by nevirapine in HIV-infected subjects under long-term successful triple combination therapy.

Authors:  P Barreiro; V Soriano; F Blanco; C Casimiro; J J de la Cruz; J González-Lahoz
Journal:  AIDS       Date:  2000-05-05       Impact factor: 4.177

3.  Interference with cell cycle progression and induction of apoptosis by dideoxynucleoside analogs.

Authors:  M Viora; G Di Genova; R Rivabene; W Malorni; A Fattorossi
Journal:  Int J Immunopharmacol       Date:  1997-06

4.  3-year suppression of HIV viremia with indinavir, zidovudine, and lamivudine.

Authors:  R M Gulick; J W Mellors; D Havlir; J J Eron; A Meibohm; J H Condra; F T Valentine; D McMahon; C Gonzalez; L Jonas; E A Emini; J A Chodakewitz; R Isaacs; D D Richman
Journal:  Ann Intern Med       Date:  2000-07-04       Impact factor: 25.391

5.  Reversion of metabolic abnormalities after switching from HIV-1 protease inhibitors to nevirapine.

Authors:  E Martínez; I Conget; L Lozano; R Casamitjana; J M Gatell
Journal:  AIDS       Date:  1999-05-07       Impact factor: 4.177

6.  Impact of switching from human immunodeficiency virus type 1 protease inhibitors to efavirenz in successfully treated adults with lipodystrophy.

Authors:  E Martínez; M A García-Viejo; J L Blanco; L Bianchi; E Buira; I Conget; R Casamitjana; J Mallolas; J M Gatell
Journal:  Clin Infect Dis       Date:  2000-11-06       Impact factor: 9.079

7.  Incorporation of zidovudine into leukocyte DNA from HIV-1-positive adults and pregnant women, and cord blood from infants exposed in utero.

Authors:  O A Olivero; G M Shearer; C A Chougnet; A A Kovacs; A L Landay; R Baker; A M Stek; M M Khoury; L A Proia; H A Kessler; B E Sha; R E Tarone; M C Poirier
Journal:  AIDS       Date:  1999-05-28       Impact factor: 4.177

8.  The HIV-1 viral protein R induces apoptosis via a direct effect on the mitochondrial permeability transition pore.

Authors:  E Jacotot; L Ravagnan; M Loeffler; K F Ferri; H L Vieira; N Zamzami; P Costantini; S Druillennec; J Hoebeke; J P Briand; T Irinopoulou; E Daugas; S A Susin; D Cointe; Z H Xie; J C Reed; B P Roques; G Kroemer
Journal:  J Exp Med       Date:  2000-01-03       Impact factor: 14.307

9.  Early activation of caspases during T lymphocyte stimulation results in selective substrate cleavage in nonapoptotic cells.

Authors:  A Alam; L Y Cohen; S Aouad; R P Sékaly
Journal:  J Exp Med       Date:  1999-12-20       Impact factor: 14.307

10.  Mitochondrial control of nuclear apoptosis.

Authors:  N Zamzami; S A Susin; P Marchetti; T Hirsch; I Gómez-Monterrey; M Castedo; G Kroemer
Journal:  J Exp Med       Date:  1996-04-01       Impact factor: 14.307

View more
  15 in total

1.  Enhanced oxidative stress and increased mitochondrial mass during efavirenz-induced apoptosis in human hepatic cells.

Authors:  N Apostolova; L J Gomez-Sucerquia; A Moran; A Alvarez; A Blas-Garcia; J V Esplugues
Journal:  Br J Pharmacol       Date:  2010-08       Impact factor: 8.739

2.  Protein quality control at the interface of endoplasmic reticulum and mitochondria by Lon protease.

Authors:  Ashutosh K Pandey; Sundararajan Venkatesh
Journal:  Br J Pharmacol       Date:  2018-12-10       Impact factor: 8.739

3.  Lower Pretreatment Gut Integrity Is Independently Associated With Fat Gain on Antiretroviral Therapy.

Authors:  Vanessa El Kamari; Carlee Moser; Corrilynn O Hileman; Judith S Currier; Todd T Brown; Liz Johnston; Peter W Hunt; Grace A McComsey
Journal:  Clin Infect Dis       Date:  2019-04-08       Impact factor: 9.079

4.  Association of circulating cytochrome c with clinical manifestations of antiretroviral-induced toxicity.

Authors:  Allison Langs-Barlow; Shanmugapriya Selvaraj; Onyema Ogbuagu; Veronika Shabanova; Eugene D Shapiro; Elijah Paintsil
Journal:  Mitochondrion       Date:  2014-11-28       Impact factor: 4.160

5.  Combination of Tenofovir and Emtricitabine with Efavirenz Does Not Moderate Inhibitory Effect of Efavirenz on Mitochondrial Function and Cholesterol Biosynthesis in Human T Lymphoblastoid Cell Line.

Authors:  Min Li; Anuoluwapo Sopeyin; Elijah Paintsil
Journal:  Antimicrob Agents Chemother       Date:  2018-08-27       Impact factor: 5.191

6.  Development of a liposomal nanodelivery system for nevirapine.

Authors:  Lakshmi N Ramana; Swaminathan Sethuraman; Udaykumar Ranga; Uma M Krishnan
Journal:  J Biomed Sci       Date:  2010-07-13       Impact factor: 8.410

7.  Choice of antiretroviral therapy differentially impacts survival of HIV-infected CD4 T cells.

Authors:  Nathan W Cummins; Amy M Sainski; Sekar Natesampillai; Gary D Bren; Andrew D Badley
Journal:  Mol Cell Ther       Date:  2014-01-03

Review 8.  The macrophage: a therapeutic target in HIV-1 infection.

Authors:  Amit Kumar; Georges Herbein
Journal:  Mol Cell Ther       Date:  2014-04-02

9.  Kinetics of microbial translocation markers in patients on efavirenz or lopinavir/r based antiretroviral therapy.

Authors:  Jan Vesterbacka; Piotr Nowak; Babilonia Barqasho; Samir Abdurahman; Jessica Nyström; Staffan Nilsson; Hiroyuki Funaoka; Tatsuo Kanda; Lars-Magnus Andersson; Magnus Gisslèn; Anders Sönnerborg
Journal:  PLoS One       Date:  2013-01-28       Impact factor: 3.240

10.  Risk Factors for Incident Diabetes in a Cohort Taking First-Line Nonnucleoside Reverse Transcriptase Inhibitor-Based Antiretroviral Therapy.

Authors:  Sumanth Karamchand; Rory Leisegang; Michael Schomaker; Gary Maartens; Lourens Walters; Michael Hislop; Joel A Dave; Naomi S Levitt; Karen Cohen
Journal:  Medicine (Baltimore)       Date:  2016-03       Impact factor: 1.889

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.